Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy.
breast cancer
chemotherapy
loco-regional treatment
metastasis
surgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Dec 2022
17 Dec 2022
Historique:
received:
10
11
2022
revised:
12
12
2022
accepted:
16
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Loco-regional therapy (LRT) in de novo metastatic breast cancer (MBC) has been investigated in several clinical trials, with heterogeneous and conflicting results. We conducted a retrospective study of de novo MBC patients treated with front-line chemotherapy (FLC) followed by LRT of the primary tumor. Our aims were to evaluate the characteristics, treatment, and oncological outcomes in terms of progression-free survival (PFS), distant progression-free survival (DPFS), and overall survival (OS) of de novo MBC. We also investigated possible subgroups of patients with better outcomes according to menopausal status, biological sub-type, location, number of metastases, and radiologic complete response after FLC. We included 61 patients in the study. After a median follow-up of 55 months, disease progression occurred in 60.7% of patients and 49.2% died. There were no significant differences in PFS, DPFS, and OS between different subgroups of de novo MBC patients. A trend toward better PFS and DPFS was observed in triple-positive tumors, without a statistically significant difference in OS. No specific subgroup of de novo MBC patients showed a statistically significant survival advantage after FLC followed by LRT of the primary tumor.
Sections du résumé
BACKGROUND
BACKGROUND
Loco-regional therapy (LRT) in de novo metastatic breast cancer (MBC) has been investigated in several clinical trials, with heterogeneous and conflicting results.
METHODS
METHODS
We conducted a retrospective study of de novo MBC patients treated with front-line chemotherapy (FLC) followed by LRT of the primary tumor. Our aims were to evaluate the characteristics, treatment, and oncological outcomes in terms of progression-free survival (PFS), distant progression-free survival (DPFS), and overall survival (OS) of de novo MBC. We also investigated possible subgroups of patients with better outcomes according to menopausal status, biological sub-type, location, number of metastases, and radiologic complete response after FLC.
RESULTS
RESULTS
We included 61 patients in the study. After a median follow-up of 55 months, disease progression occurred in 60.7% of patients and 49.2% died. There were no significant differences in PFS, DPFS, and OS between different subgroups of de novo MBC patients. A trend toward better PFS and DPFS was observed in triple-positive tumors, without a statistically significant difference in OS.
CONCLUSIONS
CONCLUSIONS
No specific subgroup of de novo MBC patients showed a statistically significant survival advantage after FLC followed by LRT of the primary tumor.
Identifiants
pubmed: 36551722
pii: cancers14246237
doi: 10.3390/cancers14246237
pmc: PMC9777012
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Cancer. 2021 Oct 15;149(8):1520-1528
pubmed: 34013530
Am J Surg. 2022 Jan;223(1):81-93
pubmed: 34325907
Surgery. 2002 Oct;132(4):620-6; discussion 626-7
pubmed: 12407345
PeerJ. 2020 Mar 18;8:e8694
pubmed: 32219021
J Clin Oncol. 2006 Jun 20;24(18):2743-9
pubmed: 16702580
Ann Surg Oncol. 2018 Oct;25(11):3141-3149
pubmed: 29777404
Ann Surg. 2019 Mar;269(3):537-544
pubmed: 29227346
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
J Pers Med. 2022 Jan 25;12(2):
pubmed: 35207645
Ann Surg. 2019 Jun;269(6):1163-1169
pubmed: 31082916
J Pers Med. 2020 Nov 13;10(4):
pubmed: 33202793
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382
pubmed: 29846104
Med Oncol. 2012 Dec;29(5):3282-90
pubmed: 22843291
Cancer. 2008 Oct 15;113(8):2011-9
pubmed: 18780312
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
Oncotarget. 2017 Apr 25;8(17):27990-27996
pubmed: 28427196
Breast Cancer Res Treat. 2011 Sep;129(2):459-65
pubmed: 21713372
Nat Rev Clin Oncol. 2015 Dec;12(12):693-704
pubmed: 26196250
Ann Surg Oncol. 2008 Dec;15(12):3384-95
pubmed: 18726129
J Clin Oncol. 2016 Jul 10;34(20):2359-65
pubmed: 27001590
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722
pubmed: 35714673
Med Oncol. 2017 Jul;34(7):119
pubmed: 28526922
Breast J. 2018 Jul;24(4):549-554
pubmed: 29498453
Breast Cancer Res Treat. 2013 Oct;141(3):507-14
pubmed: 24104881
Ann Surg Oncol. 2006 Jun;13(6):776-82
pubmed: 16614878
Cancer Metastasis Rev. 2016 Dec;35(4):495-514
pubmed: 27933405
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Ann Surg Oncol. 2013 Sep;20(9):2828-34
pubmed: 23653043
Breast Cancer Res Treat. 2017 Feb;161(3):549-556
pubmed: 28000014
Ann Surg Oncol. 2007 Aug;14(8):2187-94
pubmed: 17522944
Lancet Oncol. 2015 Oct;16(13):1380-8
pubmed: 26363985
Expert Rev Anticancer Ther. 2008 Dec;8(12):1907-12
pubmed: 19046111
Ann Surg Oncol. 2019 Feb;26(2):356-365
pubmed: 30539492
Ann Oncol. 1997 Nov;8(11):1075-80
pubmed: 9426326
Breast Cancer Res Treat. 2018 Feb;168(1):127-134
pubmed: 29164421